Overexpression of human epidermal growth factor receptor 2 (HER2) protein or amplification of the HER2 gene, which is classified as HER2-positive breast cancer, occurs in approximately 15% to 25% of all breast cancers and is associated with a poor prognosis and an increased risk of relapse [1]. This evidence concerns the gene ERBB2 and breast cancer.